🔥Telegram İfşa

A press release on our recent study: med.stanford.edu/news/all-news/…

It is a glorious day in Chicago ECOG-ACRIN Cancer Research Group spring 2023 meeting. So proud of Stanford Cancer Institute Stanford Department of Medicine oncology fellow Dr Julia Ransohoff for winning the 2023 Paul Carbone, MD Fellowship Award. Congratulations!!

Congratulations to the 2023 Paul Carbone, MD Fellowship Award recipient, Julia D. Ransohoff, MD of Stanford Medicine Stanford Health Care #TripleNegative #BreastCancer #TNBC #EAonc #mentorship #bcsm

Among patients diagnosed with cancer in Georgia and California between 2013 and 2019, only 6.8% underwent germline testing. #ASCO23 ja.ma/42tlfxo

Germline Genetic Testing After Cancer Diagnosis | Breast Cancer | JAMA | JAMA Network jamanetwork.com/journals/jama/…

A privilege to present our work on genetic testing after cancer diagnosis at ASCO today, with simultaneous JAMA publication.

DNA sequencing improves cancer treatment but remains underused. Why? usatoday.com/story/news/hea…

In 1995, Allison Walsh Allison Kurian, Rachel Rosovsky and I matriculated to med school together Harvard Medical School. Today, we were listed as the authors of 3 most read research papers in JAMA this week—how cool is that?! Go Class of ‘99! #MedTwitter MassGeneral News

Another recent article that makes JAMA Most Viewed list “Germline Genetic Testing After Cancer Diagnosis” Allison Kurian & colleagues - published with ASCO meeting jamanetwork.com/journals/jama/…

Our new paper reveals US payers’ barriers, opportunities for coverage of MCED, promising but controversial tests for multicancer early detection Health Affairs #HAScholar Kathryn A Phillips PhD Allison Kurian Christine Weldon Michael Douglas academic.oup.com/healthaffairss…

Meeting the need for germline testing - The Lancet Oncology thelancet.com/journals/lanon…

Based on 4 simulation models, breast cancer screening, treatment of stage I to III breast cancer, and treatment of metastatic breast cancer were associated with reduced breast cancer mortality between 1975 and 2019 in the US. ja.ma/47EB7zR

Deaths from breast cancer dropped 58% between 1975 and 2019 due to a combination of screening mammography and improvements in treatment, according to a new study led by Stanford Medicine clinicians and biomedical data scientists. #BreastCancer #DataScience stan.md/3Ougj7x

I am so happy to see this major collaborative effort published Stanford Plevritis Lab Allison Kurian (and Liyang Sun!) and wanted to share some of my thoughts having worked on it.

This study found low resumption of endocrine therapy and imaging post-pregnancy in breast cancer patients, with a 19% incidence of subsequent events over 10 years. ja.ma/4gEuxxQ

.Stanford Medicine-led research reveals troubling stats: only one-third of women who paused #BreastCancer treatment to get pregnant resume therapy, doubling the risk of recurrence, featuring #StanDOM's Julia Ransohoff & Allison Kurian. stan.md/4bfFh4G

"#Breast, #Colorectal, & #PancreaticCancer Mortality W/ Pathogenic Variants in #ATM, #CHEK2, or #PALB2" #DrChristineVeestra et al. #Patients w/ #Lynchsyndrome gene pathogenic variants on #germline #genetictesting had lower #colorectalcancer mortality ascopubs.org/doi/10.1200/JC…

Breast, Colorectal, and Pancreatic Cancer Mortality With Pathogenic Variants in ATM, CHEK2, or PALB2 by Allison Kurian et al. #bcsm #crcsm #pancan brnw.ch/21wR4KJ